Provided by Tiger Trade Technology Pte. Ltd.

Prothena Corp PLC

8.87
-0.0900-1.00%
Volume:118.00K
Turnover:1.04M
Market Cap:477.47M
PE:-1.70
High:9.09
Open:8.97
Low:8.65
Close:8.96
52wk High:16.67
52wk Low:4.32
Shares:53.83M
Float Shares:40.09M
Volume Ratio:0.65
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2105
EPS(LYR):-2.2746
ROE:-67.63%
ROA:-29.31%
PB:1.62
PE(LYR):-3.90

Loading ...

Prothena Unveils Pipeline Progress on Therapies Targeting Parkinson’s, Alzheimer’s, and ATTR Amyloidosis

Reuters
·
Jan 12

Paula Cobb Steps Down from Prothena Board

Reuters
·
Dec 13, 2025

Prothena Announces Board of Directors Update

THOMSON REUTERS
·
Dec 13, 2025

Prothena Highlights Advances in Protein Dysregulation Therapies for Neurodegenerative Diseases in Latest Presentation

Reuters
·
Dec 02, 2025

Prothena Is Maintained at Market Outperform by Citizens

Dow Jones
·
Dec 01, 2025

Prothena price target raised to $8 from $4 at BofA

TIPRANKS
·
Nov 24, 2025

Prothena Corporation Plc : Bofa Global Research Raises Price Objective to $8 From $4

THOMSON REUTERS
·
Nov 24, 2025

Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)

TIPRANKS
·
Nov 20, 2025

Prothena Corporation plc Held Extraordinary General Meeting

Reuters
·
Nov 20, 2025

Prothena announces poster presentation on TDP-43 CYTOPE program

TIPRANKS
·
Nov 20, 2025

Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model

Reuters
·
Nov 20, 2025

Prothena Announces Poster Presentation on Its Tdp-43 Cytope® Program at Neuroscience 2025

THOMSON REUTERS
·
Nov 20, 2025

Prothena Q3 Net Income USD -36.541 Million

Reuters
·
Nov 20, 2025

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Benzinga
·
Nov 12, 2025

Prothena Highlights Positive Phase 2 Results for Coramitug in ATTR Amyloidosis

Reuters
·
Nov 11, 2025

Prothena Highlights Phase 2 Data for Coramitug (Formerly Prx004) Published in Circulation, Official Journal of Aha

THOMSON REUTERS
·
Nov 11, 2025

Stock Track | Prothena (PRTA) Soars 5% Pre-Market as H.C. Wainwright Boosts Price Target by 50%

Stock Track
·
Nov 07, 2025

Prothena price target raised to $30 from $20 at H.C. Wainwright

TIPRANKS
·
Nov 07, 2025

Prothena Corporation Plc : H.c. Wainwright Raises Target Price to $30 From $20

THOMSON REUTERS
·
Nov 07, 2025

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

TIPRANKS
·
Nov 07, 2025